We only have this paper's title and publication details.
Read it at the sourceCaptured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The 2017 Expert Consensus Decision Pathway got a lot of attention because it takes a very practical approach to questions that clinicians and their patients have to tackle everyday but for which there was not always clean answers from the data.”
“Optimal GDMT among HFrEF patients is distressingly low, due in part to the number and complexity of medications that now constitute GDMT.”
“Relative to an ACE inhibitor and a beta-blocker alone, optimal implementation of the current guideline-directed medical therapies can extend medical survival by more than 6 years.”
No takes yet. Share an insight, caveat, or question.
Yancy et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: